Bioxytran Gets Broad Patent Coverage on 60+ Viruses
24. Oktober 2023 08:45 ET
|
BIOXYTRAN, INC.
Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
Bioxytran Interview at the Emerging Growth Conference
04. Oktober 2023 09:00 ET
|
BIOXYTRAN, INC.
Thursday, October 5, 2023 10:15 am –10:45 am ESTSmall Pharma Strategy BOSTON, MASSACHUSETTS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage...
Bioxytran to Appear on ClearThink IR’s Virtual Live Event
14. Februar 2023 09:00 ET
|
BIOXYTRAN, INC.
- Wednesday, February 15th, 2023 12:00 EST - Virtual Fireside Chat via Paltalk Platform BOSTON, MASSACHUSETTS, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”),...
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
06. Februar 2023 09:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19...
Bioxytran Interview at the Emerging Growth Conference
24. Januar 2023 14:10 ET
|
BIOXYTRAN, INC.
- Wednesday, January 25, 2023 10:50 am –11:20am EST - Discussion of the Biotech Showcase Conference BOSTON, MASSACHUSETTS, Jan. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the...
Bioxytran Interview at the Emerging Growth Conference
12. Dezember 2022 09:45 ET
|
BIOXYTRAN, INC.
Wednesday, December 14, 2022 1:45pm –2:15pm ESTDiscussion of Clinical Trial Results BOSTON, MASSACHUSETTS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a...